Alnylam Pharmaceuticals

Share on: 
Business Area(s): 
Description: 

Alnylam develops innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases. The company has produced two RNAi drugs that are approved by the FDA:  ONPATTRO® (patisiran) and GIVLAARI® (givosiran). 

Alnylam Pharma is also working on RNAi Therapeutics to treat COVID-19.

Career Page(s): 
Location(s): 
Cambridge MA
United States
ALNYLAM UK LTD.
Maidenhead
United Kingdom
Switzerland